The soluble factors analyzed in this study are key regulators of inflammation, osteoclastogenesis and metabolic syndrome, and our data suggested that systemic expression of factors promoting inflammation, metabolic disorders and osteoclastogenesis (TNF-α, leptin, adiponectin, chemerin, omentin, RANKL) were disordered in patients with PsA. Here, LEP is linked to metabolic disease.